SIL Investments Limited — Others, 06-05-2025: Copy of Newspaper Publication

SIL Investments Limited has announced a board meeting to consider the financial results for the quarter and half-year. The Indian anti-diabetes market is growing strongly, valued at about ₹20,711 crore, with insulins contributing around ₹4,367 crore despite rising use of oral anti-diabetic drugs and new GLP-1 therapies. Insulin remains critical for type 1 diabetes and insulin-deficient patients, driving steady demand. Market leaders like Novo Nordisk are consolidating insulin products, while domestic players such as Eris Lifesciences are scaling up production, highlighting sustained growth potential supported by expanding public healthcare needs.